Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

J Clin Med · 2019 · PMC6947627 · PMID 31835708

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The numerically higher pCR rate observed in the METTEN patients receiving neoadjuvant metformin compared with the reference arm did not reach statistical significance [ 14 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.